Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
Molecular studies have shown that the majority of azole resistance in Aspergillus fumigatus is associated with amino acid substitutions in the cyp51A gene. To obtain insight into azole resistance mutations, the cyp51A gene of 130 resistant and 76 susceptible A. fumigatus isolates was sequenced. Out of 130 azole-resistant isolates, 105 contained a tandem repeat of 34 bp in the promoter region and a leucine-to-histidine substitution in codon 98 (designated TR/L98H). Additionally, in 12 of these TR/L98H resistant isolates, the mutations S297T and F495I were found, and in 1 isolate, the mutation F495I was found. In eight azole-resistant isolates, known azole resistance mutations were detected in codon G54, G138, or M220. In three azole-susceptible isolates, the mutation E130D, L252L, or S400I was found and in 13 azole-susceptible isolates but also in 1 azole-resistant isolate, the mutations F46Y, G98G, M172V, N248T, D255E, L358L, E427K, and C454C were found. All of the nonsynonymous mutations, apart from the mutations in codons G54, G138, and M220 and L98H, were located at the periphery of the protein, as determined by a structural model of the A. fumigatus Cyp51A protein, and were predicted neither to interact with azole compounds nor to affect structural integrity. Therefore, this wide diversity of mutations in the cyp51A gene in azole-susceptible A. fumigatus isolates is not correlated with azole resistance. Based on the Cyp51A protein homology model, the potential correlation of a mutation to azole resistance can be predicted.
Snelders
Eveline
E
Radboud University Nijmegen Medical Center, Antonie van Leeuwenhoeklaan, Nijmegen HB, The Netherlands. e.snelders@mmb.umcn.nl
Karawajczyk
Anna
A
Schaftenaar
Gijs
G
Verweij
Paul E
PE
Melchers
Willem J G
WJ
D019943:Amino Acid Substitution; D000935:Antifungal Agents / Q000494:pharmacology*; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics*; D001393:Azoles / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry* / Q000235:genetics*; D025141:Drug Resistance, Fungal / Q000235:genetics; D005656:Fungal Proteins / Q000737:chemistry* / Q000235:genetics*; D005800:Genes, Fungal; D006801:Humans; D066298:In Vitro Techniques; D008958:Models, Molecular; D020125:Mutation, Missense; D011487:Protein Conformation; D040681:Structural Homology, Protein; D020080:Tandem Repeat Sequences
D000935:Antifungal Agents; D001393:Azoles; D005656:Fungal Proteins; D003577:Cytochrome P-450 Enzyme System; C465526:cytochrome P-450 CYP51A, Aspergillus
Drug Resist Updat. 2009 Dec;12(6):141-7
19879181
Antimicrob Agents Chemother. 2004 Jul;48(7):2747-50
15215142
Emerg Infect Dis. 2009 Jul;15(7):1068-76
19624922
Pharmacol Ther. 1995;67(1):79-100
7494862
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
8744570
Nat Rev Genet. 2007 Mar;8(3):206-16
17304246
Antimicrob Agents Chemother. 2004 Feb;48(2):568-74
14742211
Antimicrob Agents Chemother. 2009 Aug;53(8):3487-95
19470512
Lancet. 2007 Jul 7;370(9581):102
17617278
Bioorg Med Chem. 2004 Jun 1;12(11):2937-50
15142553
Future Microbiol. 2006 Oct;1(3):283-93
17661641
FEMS Microbiol Lett. 2007 Dec;277(1):37-43
17986082
J Gen Virol. 2006 Jan;87(Pt 1):103-113
16361422
N Engl J Med. 2007 Apr 5;356(14):1481-3
17409336
Med Mycol. 2010 Feb;48(1):197-200
20055745
Antimicrob Agents Chemother. 2003 Mar;47(3):1120-4
12604551
Clin Microbiol Rev. 2009 Apr;22(2):291-321, Table of Contents
19366916
Antimicrob Agents Chemother. 2008 Jul;52(7):2468-72
18474574
Biochem Biophys Res Commun. 2005 Dec 9;338(1):418-22
16153595
Appl Environ Microbiol. 2009 Jun;75(12):4053-7
19376899
Fungal Genet Biol. 2002 Aug;36(3):199-206
12135575
Int J Antimicrob Agents. 2006 Nov;28(5):450-3
17034993
Antimicrob Agents Chemother. 2007 Jun;51(6):1897-904
17371828
PLoS Med. 2008 Nov 11;5(11):e219
18998768
Med Mycol. 2005 May;43 Suppl 1:S313-9
16110826
J Enzyme Inhib. 1999;14(3):175-92
10445042